$ZIVO
Zivo Bioscience, Inc.

2024 Q2 Form 10-Q Financial Statement

#000165495424006082 Filed on May 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q1
Revenue $0.00 $35.72K $0.00
YoY Change -100.0%
Cost Of Revenue $0.00 $23.22K $0.00
YoY Change -100.0%
Gross Profit $0.00 $12.50K $0.00
YoY Change -100.0%
Gross Profit Margin 35.0%
Selling, General & Admin $5.977M $975.6K $1.568M
YoY Change 331.54% -37.8% 16.46%
% of Gross Profit 7803.31%
Research & Development $2.252M $312.8K $401.8K
YoY Change 409.45% -22.16% -40.89%
% of Gross Profit 2501.74%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $8.230M $1.288M $1.970M
YoY Change 350.39% -34.61% -2.78%
Operating Profit -$8.230M -$1.276M -$1.970M
YoY Change 351.22% -35.24% -2.78%
Interest Expense $6.766K $2.648K $2.968K
YoY Change -78.72% -10.78% 64.43%
% of Operating Profit
Other Income/Expense, Net $6.766K $2.648K $2.968K
YoY Change -97.26% -10.78% -264.43%
Pretax Income -$8.236M -$1.278M -$1.973M
YoY Change 297.78% -35.21% -2.72%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$8.236M -$1.278M -$1.973M
YoY Change 297.78% -35.21% -2.72%
Net Earnings / Revenue -3579.19%
Basic Earnings Per Share
Diluted Earnings Per Share -$2.78 -$0.47 -$0.21
COMMON SHARES
Basic Shares Outstanding 2.832M shares 2.778M shares 9.420M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.470K $138.6K $208.6K
YoY Change -88.28% -33.54% -96.84%
Cash & Equivalents $208.6K
Short-Term Investments
Other Short-Term Assets $492.7K $568.2K $719.6K
YoY Change -3.21% -21.04% -15.86%
Inventory
Prepaid Expenses
Receivables $0.00 $3.740K
Other Receivables $0.00 $0.00
Total Short-Term Assets $495.1K $710.6K $928.2K
YoY Change -6.59% -23.44% -87.55%
LONG-TERM ASSETS
Property, Plant & Equipment $48.40K $73.72K $0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $80.46K $105.8K $199.8K
YoY Change -55.36% -47.04% -14.6%
TOTAL ASSETS
Total Short-Term Assets $495.1K $710.6K $928.2K
Total Long-Term Assets $80.46K $105.8K $199.8K
Total Assets $575.6K $816.4K $1.128M
YoY Change -18.97% -27.62% -85.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.093M $705.8K $670.3K
YoY Change -14.13% 5.31% 28.81%
Accrued Expenses $1.003M $1.288M $563.7K
YoY Change 47.09% 128.46% 86.77%
Deferred Revenue
YoY Change
Short-Term Debt $287.5K $460.1K $538.3K
YoY Change -74.14% -14.54% -3.66%
Long-Term Debt Due $240.0K $240.0K $240.0K
YoY Change 0.0% 0.0% 0.0%
Total Short-Term Liabilities $2.871M $3.085M $2.791M
YoY Change -24.53% 10.56% -5.71%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $79.03K
YoY Change -45.17%
Total Long-Term Liabilities $0.00 $0.00 $79.03K
YoY Change -100.0% -100.0% -45.17%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.871M $3.085M $2.791M
Total Long-Term Liabilities $0.00 $0.00 $79.03K
Total Liabilities $2.871M $3.085M $2.870M
YoY Change -25.52% 7.52% -7.54%
SHAREHOLDERS EQUITY
Retained Earnings -$133.1M -$124.9M -$117.8M
YoY Change 11.05% 6.01%
Common Stock $3.319K $2.791K $9.420K
YoY Change -64.77% -70.37%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.296M -$2.269M -$1.742M
YoY Change
Total Liabilities & Shareholders Equity $575.6K $816.4K $1.128M
YoY Change -18.97% -27.62% -85.33%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income -$8.236M -$1.278M -$1.973M
YoY Change 297.78% -35.21% -2.72%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$623.6K -$1.699M -$2.129M
YoY Change -36.73% -20.19% -25.6%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 487.5K $1.563M $538.3K
YoY Change -38.92% 190.42% -3.66%
NET CHANGE
Cash From Operating Activities -623.6K -$1.699M -$2.129M
Cash From Investing Activities $0.00 $0.00
Cash From Financing Activities 487.5K $1.563M $538.3K
Net Change In Cash -136.2K -$135.7K -$1.591M
YoY Change -27.39% -91.47% -30.93%
FREE CASH FLOW
Cash From Operating Activities -$623.6K -$1.699M -$2.129M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 zivo Accumulated Deficit
AccumulatedDeficit
124860200 usd
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001101026
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2789655 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2382356 shares
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-40449
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
Zivo Bioscience, Inc.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0699977
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
21 East Long Lake Road
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Ste. 100
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Bloomfield Hills
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MI
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
48304
CY2024Q1 dei City Area Code
CityAreaCode
248
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
452-9866
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2831943 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000 shares
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1278486 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1973142 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-10622 usd
CY2023Q1 zivo Employee And Director Equity Based Compensation
EmployeeAndDirectorEquityBasedCompensation
242102 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1973142 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1741662 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2205843 usd
CY2024Q1 zivo Employee And Director Equity Based Compensation
EmployeeAndDirectorEquityBasedCompensation
112104 usd
CY2024Q1 zivo Private Sales Of Common Stock Other Amount
PrivateSalesOfCommonStockOtherAmount
972544 usd
CY2024Q1 zivo Private Sales Of Common Stock Related Party Amount
PrivateSalesOfCommonStockRelatedPartyAmount
130782 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1278486 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-2268899 usd
CY2024Q1 zivo Research And Development Expenses
ResearchAndDevelopmentExpenses
0 usd
CY2023Q1 zivo Research And Development Expenses
ResearchAndDevelopmentExpenses
125030 usd
CY2024Q1 zivo Contra Rd Expense Related To Personnel And Third Party Expenses
ContraRDExpenseRelatedToPersonnelAndThirdPartyExpenses
0 usd
CY2023Q1 zivo Contra Rd Expense Related To Personnel And Third Party Expenses
ContraRDExpenseRelatedToPersonnelAndThirdPartyExpenses
31274 usd

Files In Submission

Name View Source Status
0001654954-24-006082-index-headers.html Edgar Link pending
0001654954-24-006082-index.html Edgar Link pending
0001654954-24-006082.txt Edgar Link pending
0001654954-24-006082-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
zivo-20240331.xsd Edgar Link pending
zivo_10q.htm Edgar Link pending
zivo_ex311.htm Edgar Link pending
zivo_ex312.htm Edgar Link pending
zivo_ex321.htm Edgar Link pending
zivo_ex322.htm Edgar Link pending
zivo-20240331_def.xml Edgar Link unprocessable
zivo-20240331_lab.xml Edgar Link unprocessable
zivo-20240331_pre.xml Edgar Link unprocessable
zivo_10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
zivo-20240331_cal.xml Edgar Link unprocessable